Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Why Is Mesoblast Stock Up Today?

Mesoblast develops cell-based therapies derived from mesenchymal lineage cells, targeting a range of inflammatory and immune-mediated conditions, with its lead therapy having achieved regulatory approval in certain markets for specific paediatric and adult treatment indications following an extended clinical development and regulatory review process.

Sonal Goyal | 15 July 2026

Why Is Neuren Pharmaceuticals Stock Up Today?

Neuren Pharmaceuticals develops drug therapies for neurodevelopmental disorders, with its lead approved therapy treating Rett syndrome, a rare genetic neurodevelopmental disorder, alongside a broader pipeline of drug candidates targeting other neurodevelopmental conditions.

Sonal Goyal | 15 July 2026

Is EBOS Group Worth a Look After This Pullback?

EBOS Group distributes healthcare and pharmaceutical products, along with animal care products, across Australia and New Zealand, operating a diversified distribution business that supplies pharmacies, hospitals, veterinary clinics and other healthcare and animal care customers.

Sonal Goyal | 15 July 2026

Is 4DMedical Worth Considering After This Extraordinary Rally?

4DMedical develops advanced lung imaging technology, including its XV Technology platform, which provides functional imaging of lung ventilation using standard X-ray equipment, offering an alternative to more invasive or expensive lung function testing methods used in respiratory disease diagnosis and monitoring.

Sonal Goyal | 15 July 2026

Why Is Ansell Stock Climbing?

Ansell designs and manufactures protective gloves and personal protective equipment, serving both healthcare customers (through surgical and examination gloves) and industrial customers (through work safety gloves and protective clothing) across a global distribution network.

Sonal Goyal | 15 July 2026

Is Cochlear Worth Considering After This Extended Decline?

Cochlear designs, manufactures and supplies cochlear implants and related hearing solutions for people with moderate to profound hearing loss, holding a leading global position in the cochlear implant market, with products distributed across numerous international healthcare markets.

Sonal Goyal | 15 July 2026

Is CSL Worth Considering After Its Sharp Decline?

CSL is a global biotherapeutics company, developing and manufacturing plasma-derived therapies, vaccines and other biologic medicines, with a significant global plasma collection network supporting its core CSL Behring business, alongside its Seqirus vaccines division and CSL Vifor iron deficiency and nephrology business.

Sonal Goyal | 15 July 2026

Nyrada Inc (ASX:NYR) Surges 38.55% as Healthcare Stock Extends One-Year Gain

The latest rise also needs to be viewed against the stock’s longer-term performance. ASX:NYR is up 94.92% over one year. That contrast helps place the session in perspective. A substantial daily gain can attract attention, but it does not automatically redefine the longer-term trend. …

Aditi Sarkar | 15 July 2026

Emvision Medical Devices Ltd (ASX:EMV) Jumps 15.41% as Shares Reach AUD 1.76

The move should be considered against the stock’s longer-term performance. ASX:EMV is up 1.73% over the past year. A single-session gain and a one-year return measure different periods, so both figures are useful when assessing the latest price action. Based strictly on the supplied …

Aditi Sarkar | 15 July 2026

Adherium Ltd (ASX:ADR) Falls 15.39% as Shares Slide to AUD 0.11

The fall also needs to be viewed against the stock’s longer-term performance. ASX:ADR is down 81.29% over the past year. A sharp daily decline can look very different when compared with a one-year gain or loss, making the longer timeframe important when assessing the …

Aditi Sarkar | 15 July 2026
Support

Hi! How can we help you today?

Loading…